Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT – Research Report) today and set a price target of $120.00. The company’s shares closed last Monday at $47.00.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.2% and a 31.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $94.50 average price target, representing a 102.1% upside. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
The company has a one-year high of $64.94 and a one-year low of $30.15. Currently, Global Blood Therapeutics has an average volume of 745.4K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GBT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.